Evaxion A/S expected to post a loss of 31 cents a share - Earnings Preview
Evaxion A/S <EVAX.OQ> expected to post a loss of 31 cents a share - Earnings Preview
Evaxion A/S EVAX.OQ EVAX.O is expected to show a fall in quarterly revenue when it reports results on August 20 for the period ending June 30 2026
LSEG's mean analyst estimate for Evaxion A/S is for a loss of 31 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Evaxion A/S is $10.00, about 219.5% above its last closing price of $3.13
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2026 | -0.45 | -0.30 | -0.50 | Missed | -64.8 |
Dec. 31 2026 | -0.33 | -0.30 | -1.00 | Missed | -237.1 |
Sep. 30 2025 | 0.40 | 0.40 | 0.50 | Beat | 25 |
Jun. 30 2025 | -0.66 | -0.66 | -1.00 | Missed | -51.5 |
Mar. 31 2025 | -0.65 | -0.65 | -0.50 | Beat | 23.1 |
Dec. 31 2024 | -3.88 | -3.88 | -3.50 | Beat | 9.8 |
Sep. 30 2024 | -1.22 | -1.43 | -0.20 | Beat | 86 |
Jun. 30 2024 | -1.78 | -1.95 | -0.60 | Beat | 69.2 |
This summary was machine generated August 18 at 12:32 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Recent news on Evaxion A/S
See all newsEvaxion A/S reports results for the quarter ended June 30 - Earnings Summary
Denmark's Evaxion Q2 net loss narrows on lower expenses
Brief: Evaxion Q2 Basic EPS USD -0.01
Evaxion A/S expected to post a loss of 31 cents a share - Earnings Preview
Brief: Evaxion A/S - Expands Pipeline Of Cancer Vaccine Programs With Evx-05 Against Brain Cancer Glioblastoma